Business Wire

Versum Materials and NuMat Technologies to Commercialize Next-Generation Adsorbent Technology for Delivery of Dopant Gases

Del

Versum Materials, Inc. (NYSE: VSM), a leading global materials supplier to the semiconductor industry, and NuMat Technologies, a pioneer in the design and integration of atomically-engineered materials into gas delivery, separation and purification systems, today announced a global, commercial agreement to offer a new line of products for the safe storage and delivery of dopant gases such as arsine, phosphine and boron trifluoride. The new product line is called ION-X ® and is based on revolutionary Metal Organic Frameworks (MOFs), which can selectively adsorb, store and safely deliver ultrahigh purity gases at sub-atmospheric pressures. ION-X® offers performance advantages over traditional carbon-based adsorbent technology used in the ion implant processes for the manufacture of semiconductor devices.

Jim Minicucci, general manager for Versum's Process Materials, Asia commented, "NuMat and Versum are combining their respective leadership positions, with NuMat manufacturing the proprietary MOFs and Versum harnessing its world-class global footprint to manufacture, commercialize, and distribute the ION-X® product globally. Building on our long-history in Specialty Gases, we plan to design and construct a new ION-X® dopant gas fill plant at our production site in Sihwa, South Korea."

“We are excited about working together with NuMat Technologies to deliver ION-X® products to our global customer base. ION-X® represents a new and differentiated growth opportunity, is complementary to our Process Materials business, and further aligns with our core competencies as a leading specialty gas manufacturer and supplier,” stated Ed Shober, Senior Vice President of Materials at Versum Materials.

“We are pleased to announce our agreement with Versum Materials to globally commercialize ION-X®. This relationship with Versum represents a strategic pairing of NuMat’s differentiated technology platform with Versum’s operational, quality and commercial leadership in the semiconductor industry. We look forward to executing against a shared mission of delivering value and innovation to customers,” stated Ben Hernandez, Chief Executive Officer at NuMat Technologies.

About Versum Materials
Versum Materials, Inc. (NYSE: VSM) is a leading electronic materials company providing high-purity chemicals and gases, delivery systems, services and materials expertise to meet the evolving needs of the global semiconductor and display industries. Derived from the Latin word for “toward,” the name “Versum” communicates the company’s deep commitment to helping customers move toward the future by collaborating, innovating and creating cutting-edge solutions.

A global leader in technology, quality, safety and reliability, Versum Materials is one of the world’s leading suppliers of next-generation CMP slurries, ultrathin dielectric and metal film precursors, formulated cleans and etching products, and delivery equipment that has revolutionized the semiconductor industry. Versum Materials has annual sales of approximately $1 billion, 2,000 employees and 10 major facilities in Asia and North America. It is headquartered in Tempe, Arizona. Prior to its separation on October 1, 2016, Versum Materials had operated for more than three decades as a division of Air Products and Chemicals, Inc. (NYSE: APD). For additional information, please visit http://www.versummaterials.com.

About NuMat Technologies
NuMat Technologies, Inc. is an advanced technology company innovating at the intersection of big data, material science, and hardware systems. We work with leading partners in the semiconductor, healthcare, and industrial sectors to design material-enabled products that meet the most demanding customer requirements. NuMat is a recognized pioneer in the field of Metal-Organic Frameworks (“MOFs”) - an emerging class of nanoporous materials. MOFs have surface areas far exceeding those of traditional adsorbents, and can be programmed to uniquely interact with target molecules at the atomic level. NuMat’s expertise lies in the design and integration of MOFs into next-generation storage, separation, and purification systems. In doing so, NuMat enables previously unachievable form factors, performance, and cost-advantaged production economics. NuMat provides a total solutions platform for product commercialization, pairing world-class material discovery software with application development and manufacturing expertise. www.numat-tech.com

Versum Investor Inquiries:
Nahla A. Azmy, 610-481-7499
Nahla.Azmy@versummaterials.com
or
Versum Media Inquiries:
Tiffany Zinn, 480-282-6475
Tiffany.Zinn@versummaterials.com
or
NuMat Media Inquiries:
Aileron Communications
Peter Gray, 312-629-9400
pgray@aileroninc.com

The Versum Materials logo and Versum are registered trademarks of Versum Materials, Inc. or its affiliates. ION-X is a registered trademark of NuMat Technologies. All rights reserved.

Forward-Looking Information:

This press release contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements may be identified by references to future periods, and include statements about the anticipated success of our relationship with NuMat, the anticipated success of ION-X® over competing technologies that may become available, our ability to successfully design and construct a new ION-X® dopant gas fill plant in Sihwa, South Korea, our ability to successfully compete as a leading materials supplier to the semiconductor industry, and other matters. These forward-looking statements are based on management’s reasonable expectations and assumptions as of the date the statements were made. Actual results and the outcomes of future events may differ materially from those expressed or implied in the forward-looking statements because of a number of risks and uncertainties, including, without limitation, the risk factors described in our filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the fiscal year ended September 30, 2016, and in our periodic filings. Versum Materials disclaims any obligation or undertaking to disseminate any updates or revisions to the forward-looking statements.

Contact information

Versum Investor Inquiries:
Nahla A. Azmy, 610-481-7499
Nahla.Azmy@versummaterials.com
or
Versum Media Inquiries:
Tiffany Zinn, 480-282-6475
Tiffany.Zinn@versummaterials.com
or
NuMat Media Inquiries:
Aileron Communications
Peter Gray, 312-629-9400
pgray@aileroninc.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers17.2.2018 21:00Pressemelding

Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im

CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 08:00Pressemelding

Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates

Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 18:26Pressemelding

Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a

General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 17:05Pressemelding

General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges

Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 09:03Pressemelding

Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o

Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 08:00Pressemelding

Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and